Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425555 · ClinicalTrials.gov registry record · Phase 2
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 139
- Enrollment target
NCT00425555 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 139 participants.
The verdict
NCT00425555, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 139 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
Interventions
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2007-01 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00425555
The ClinicalTrials.gov registry entry for NCT00425555 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panobinostat is the first listed.
NCT00425555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00425555 about?
NCT00425555 is a clinical study titled "Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma". This study will evaluate the safety and efficacy of LBH489B in adult patients with refractory Cutaneous T-Cell Lymphoma.
What is the current status of trial NCT00425555?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2007-01. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00425555?
The interventions under investigation include: Panobinostat (DRUG).
Who is sponsoring clinical trial NCT00425555?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.